Company intelligence / Profile preview

Rgene

The Woodlands, Texas, United Statesin.marketscreener.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Rgene developed nucleic acid-based therapeutics with a novel delivery technology for RNA and DNA. Their compounds included RGG-0853 for ovarian cancer and RGA-1512 for leukemia. The company was later acquired by Targeted Genetics.

Therapeutic areas: Oncology
Modalities: Nucleic acid-based therapeuticsRNADNACationic lipid vector
Industry: Biotech

Drug pipeline

1 asset

RGC-1503

Unknown

Partnerships

ABVC BioPharmaFournierRgene Corporation

Beyond the preview

Go deeper on Rgene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rgene.

Explore the full profile